PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 20 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $56,000 | -70.8% | 320,642 | 0.0% | 0.00% | – |
| Q2 2022 | $192,000 | -54.6% | 320,642 | 0.0% | 0.00% | – |
| Q1 2022 | $423,000 | -42.1% | 320,642 | +14.4% | 0.00% | – |
| Q4 2021 | $731,000 | -16.2% | 280,403 | -0.1% | 0.00% | – |
| Q3 2021 | $872,000 | +19.8% | 280,589 | +43.3% | 0.00% | – |
| Q2 2021 | $728,000 | -12.8% | 195,860 | -18.9% | 0.00% | – |
| Q1 2021 | $835,000 | +7.2% | 241,513 | +4.1% | 0.00% | – |
| Q4 2020 | $779,000 | -6.0% | 232,036 | -1.8% | 0.00% | – |
| Q3 2020 | $829,000 | -20.2% | 236,192 | +4.5% | 0.00% | – |
| Q2 2020 | $1,039,000 | +46.3% | 225,934 | +5.3% | 0.00% | – |
| Q1 2020 | $710,000 | -69.4% | 214,659 | -43.4% | 0.00% | – |
| Q4 2019 | $2,318,000 | +205.0% | 379,434 | +108.1% | 0.00% | – |
| Q3 2019 | $760,000 | -68.2% | 182,346 | +0.1% | 0.00% | -100.0% |
| Q2 2019 | $2,389,000 | +229.5% | 182,095 | +138.6% | 0.00% | – |
| Q1 2019 | $725,000 | – | 76,304 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |